Are there restrictions on the use of natalizumab for the treatment of Crohn disease?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print
Answer

This drug was initially taken off of the market in 2005 as a result of reported cases of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis [2] ; it was then reintroduced into the market with restrictions for the indication of refractory multiple sclerosis in 2006 and Crohn disease in 2008.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!